Inoue M
Department of Obstetrics and Gynecology, Osaka University Medical School.
Nihon Sanka Fujinka Gakkai Zasshi. 1993 Aug;45(8):751-62.
The recent advances in molecular biology have led to a concept that carcinomas arise from the accumulation of a series of genetic alterations involving activation of protooncogenes and inactivation of tumor suppressor genes. The present study was designed to elucidate that such processes take place in the tumorigenesis of the uterine endometrium as well. The incidence of ras gene mutation, which were mostly composed of the point mutations of k-ras codons 12 and 13, was higher in carcinomas (31%) than atypical hyperplasias (15%), with marginal significance, but has not been associated with aggressiveness of the carcinomas. Thus, k-ras activations may occur as an early event in tumorigenesis. Mutations of tumor suppressor gene, p53, were detected in 24% of carcinomas and 8% of atypical hyperplasia, while they are not statistically different. The p53 mutations were associated with poorly differentiated adenocarcinomas. The most common pattern of the base change detected in endometrial carcinomas was the transition from G:C to A:T. The p53 mutations at CpG sites were frequent, especially at codon 248. Loss of heterozygosity (LOH) was more frequently detected than the mutations and most cases with LOH harbored the mutations, suggesting that allelic loss may precede the mutation in the tumorigenesis of endometrium. Expression of p53 was well correlated with type of the p53 mutation and its overexpression is associated with aggressive clinical behavior, suggesting the possible application of p53 as a prognostic indicator. The other tumor suppressor genes, Retinoblastoma gene (RB) and DCC gene, were also involved in the endometrial carcinogenesis. LOH and abnormal m-RNA of RB were detected in 15% and 33% of carcinomas, respectively, and associated with advanced clinical stage and poorly differentiated adenocarcinomas. LOH of DCC was also detected in some cases while that of APC was not detected. Thus, tumor suppressor genes may also play an important role as later events in carcinogenesis by inactivation mechanism consisting of the loss of one chromosomal allele and/or mutation of the gene in the remaining allele. Human papillomavirus (HPV) DNA type 16 was curiously detected in 5% of cases by both Southern blot and in situ hybridization analyses. Consequently, two third of endometrial carcinomas examined in the present study for ras, p53, RB, DCC, APC and HPV showed abnormality of at least one of these genes. The abnormality of multiple genes may contribute as an etiologic role to multisteps in carcinogenesis of the endometrium.
分子生物学的最新进展引出了一个概念,即癌是由一系列涉及原癌基因激活和肿瘤抑制基因失活的基因改变积累所致。本研究旨在阐明此类过程也发生在子宫内膜的肿瘤发生过程中。ras基因突变的发生率在癌(31%)中高于非典型增生(15%),其中大多数由k-ras密码子12和13的点突变组成,具有边缘显著性,但与癌的侵袭性无关。因此,k-ras激活可能作为肿瘤发生的早期事件出现。肿瘤抑制基因p53的突变在24%的癌和8%的非典型增生中被检测到,不过它们在统计学上无差异。p53突变与低分化腺癌相关。在子宫内膜癌中检测到的碱基变化最常见的模式是从G:C到A:T的转换。在CpG位点的p53突变很常见,尤其是在密码子248处。杂合性缺失(LOH)比突变更频繁地被检测到,并且大多数有LOH的病例都伴有突变,这表明在子宫内膜肿瘤发生过程中,等位基因缺失可能先于突变。p53的表达与p53突变类型密切相关,其过度表达与侵袭性临床行为相关,这表明p53可能作为一种预后指标。其他肿瘤抑制基因,视网膜母细胞瘤基因(RB)和DCC基因,也参与了子宫内膜癌的发生。分别在15%和33%的癌中检测到RB的LOH和异常mRNA,并且它们与临床晚期和低分化腺癌相关。在一些病例中也检测到了DCC的LOH,而未检测到APC的LOH。因此,肿瘤抑制基因可能也通过由一个染色体等位基因的缺失和/或剩余等位基因中的基因突变组成的失活机制,在癌变的后期事件中发挥重要作用。通过Southern印迹和原位杂交分析,在5%的病例中奇怪地检测到了人乳头瘤病毒(HPV)16型DNA。因此,在本研究中对ras、p53、RB、DCC、APC和HPV进行检测的子宫内膜癌中,三分之二显示出这些基因中至少一个的异常。多个基因的异常可能在子宫内膜癌发生的多步骤过程中作为病因起作用。